Advancing towards a universal platform for iPSC-based therapies: an interview with Boris Greber
Human induced pluripotent stem cells (iPSCs) are paving the way for next-generation cell therapies, offering faster development times and expanded accessibility for a wide range of diseases. In this Q&A, Boris Greber, Head of Research and Development, iPSC/CT at Catalent (NJ, USA), delves into the role of iPSCs as the foundation for cellular therapies and introduces the innovative concept of a universal platform to revolutionize iPSC-based treatments.
This Q&A has been adapted from an interview, read the original opinion piece here.
This Q&A is part of the RegMedNet Spotlight on iPSCs. Click here to view the full feature and discover expert insights on this
This content was provided by Catalent.
